Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Metformin 850 mg Clear all

Conditions: Healthy
Interventions: Lesinurad 400 mg, Metformin 850 mg, Furosemide 40 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Endometrial Hyperplasia, Endometrial Hyperplasia Without Atypia
Interventions: Metformin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Southern Pines, North Carolina • Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Metformin; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Other Conditions That May Be A Focus of Clinical Attention
Interventions: Metformin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia
Interventions: placebo, SEP-363856, metformin; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Oakland Park, Florida • Marlton, New Jersey

Conditions: Diabetes
Interventions: Promotora-led Intervention, Metformin Therapy, Usual Care; Behavioral · Drug · Other
Lead sponsor: Temple University; Other
Eligibility: 20 Years to 75 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 59 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer, Depression, Fatigue, Sleep Disorders
Interventions: Metformin, Placebo; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 252
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 185 more

Conditions: Overweight, Autism Spectrum Disorder
Interventions: Metformin, Placebo; Drug
Lead sponsor: Holland Bloorview Kids Rehabilitation Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Glioblastoma
Interventions: Paxalisib, Metformin, Ketogenic Diet; Drug · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prediabetes
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HER2-positive Breast Cancer
Interventions: Taxotere, Carboplatin, Herceptin + Pertuzumab, Metformin; Drug
Lead sponsor: Qamar Khan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more

Conditions: Melanoma
Interventions: Vemurafenib, Metformin; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: metformin hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 27
States / cities: Duarte, California • Los Angeles, California • South Pasadena, California + 18 more

Conditions: Breast Cancer
Interventions: metformin hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Atlanta, Georgia • Nashville, Tennessee

Conditions: Prediabetes
Interventions: metformin, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy
Interventions: Treatment A: Canagliflozin tablet, Treatment A: Metformin IR tablets, Treatment B: Canagliflozin/metformin fixed dose combination tablets; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide, metformin, repaglinide and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Miami, Florida • Tacoma, Washington

Conditions: Complex Atypical Hyperplasia, Endometrial Cancer
Interventions: Metformin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Cincinnati, Ohio

Conditions: Endometrial Cancer
Interventions: Metformin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer Prevention
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 54 Years · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Prostate Cancer
Interventions: Metformin, Lifestyle Modification; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2036
U.S. locations: 4
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK2330672, Placebo, Metformin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Adults
Interventions: KP-001, Metformin, Midazolam, Clarithromycin; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

Metformin and Furosemide Drug-Drug Interaction Study

Metformin for the Treatment of Endometrial Hyperplasia

Metformin for Rising PSA Remote Trial

Genetic Basis for Variation in the Renal Elimination of Metformin

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

Intervention to Promote Weight Loss in Latinas At-risk for Diabetes

Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo

Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery

Metformin and Muscle in Insulin-resistant Older Veterans

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants